

Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans

Citation for published version (APA):

Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., Kornips, C. F. P., Hesselink, M. K. C., Kunz, I., Schrauwen-Hinderling, V., Blaak, E. E., Auwerx, J., & Schrauwen, P. (2011). Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. *Cell Metabolism*, 14(5), 612-22. <https://doi.org/10.1016/j.cmet.2011.10.002>

Document status and date:

Published: 01/01/2011

DOI:

[10.1016/j.cmet.2011.10.002](https://doi.org/10.1016/j.cmet.2011.10.002)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 02 Nov. 2021

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

Silvie Timmers,^{1,2,8} Ellen Konings,^{2,8} Lena Bilet,² Riekelt H. Houtkooper,⁵ Tineke van de Weijer,² Gijs H. Goossens,² Joris Hoeks,² Sophie van der Krieken,² Dongryeol Ryu,⁵ Sander Kersten,⁶ Esther Moonen-Kornips,² Matthijs K.C. Hesselink,³ Iris Kunz,⁷ Vera B. Schrauwen-Hinderling,⁴ Ellen E. Blaak,² Johan Auwerx,⁵ and Patrick Schrauwen^{1,2,*}

¹Top Institute Food and Nutrition (TIFN), 6700 Wageningen, The Netherlands

²Department of Human Biology

³Department of Human Movement Sciences

⁴Department of Radiology

NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands

⁵Laboratory for Integrative and Systems Physiology, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland

⁶Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition, Wageningen University, 6700 Wageningen, The Netherlands

⁷DSM Nutritional Products Ltd., 4303 Kaiseraugst, Switzerland

⁸These authors contributed equally to this work

*Correspondence: p.schrauwen@maastrichtuniversity.nl

DOI 10.1016/j.cmet.2011.10.002

SUMMARY

Resveratrol is a natural compound that affects energy metabolism and mitochondrial function and serves as a calorie restriction mimetic, at least in animal models of obesity. Here, we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study for 30 days. Resveratrol significantly reduced sleeping and resting metabolic rate. In muscle, resveratrol activated AMPK, increased SIRT1 and PGC-1 α protein levels, increased citrate synthase activity without change in mitochondrial content, and improved muscle mitochondrial respiration on a fatty acid-derived substrate. Furthermore, resveratrol elevated intramyocellular lipid levels and decreased intrahepatic lipid content, circulating glucose, triglycerides, alanine-aminotransferase, and inflammation markers. Systolic blood pressure dropped and HOMA index improved after resveratrol. In the postprandial state, adipose tissue lipolysis and plasma fatty acid and glycerol decreased. In conclusion, we demonstrate that 30 days of resveratrol supplementation induces metabolic changes in obese humans, mimicking the effects of calorie restriction.

INTRODUCTION

In our western society, the number of age-related chronic diseases such as obesity, diabetes, and cancer increases progressively (Crews, 2005). The only nonpharmacological intervention known to date to alleviate these deleterious conditions is

calorie restriction. Reduction of calorie intake to 30%–50% below ad libitum levels or every-other-day feeding can delay the onset of age-related diseases, improve stress resistance, and decelerate functional decline (Barger et al., 2003; Goodrick et al., 1990; McCay et al., 1989). Although short-term dietary restriction has metabolic effects in humans such as lowering metabolic rate (Heilbronn et al., 2006), improving insulin sensitivity (Larson-Meyer et al., 2006; Lim et al., 2011), and reducing cardiovascular risk factors (Lefevre et al., 2009), eating less for the sake of creating a desirable metabolic profile is unlikely to gain widespread compliance. As such, the focus has been on the development of calorie restriction mimetics that evoke some of the benefits of calorie restriction without an actual reduction in calorie intake. In that respect, sirtuins are considered an important molecular target (Cantó and Auwerx, 2009). Indeed, it was suggested that the yeast *Sir2* gene (Lin et al., 2000) or its worm (Tissenbaum and Guarente, 2001) and fly (Rogina and Helfand, 2004) orthologs are required for the effects of calorie restriction, although the relevance of the role of Sir2/SIRT1 as a stricto sensu longevity regulator is debated (Burnett et al., 2011). What is clear, however, is that mammalian SIRT1 plays a context-dependent role in health span regulation, for instance by mediating effects in metabolic stress situations, such as high-fat-diet-induced obesity (Baur et al., 2006; Lagouge et al., 2006; Pearson et al., 2008). As such, SIRT1 confers protection against aging-associated metabolic diseases such as glucose intolerance and cancer (Herranz et al., 2010; Pearson et al., 2008; Rutanen et al., 2010). In light of the growing number of patients suffering from metabolic diseases, compounds that activate SIRT1 directly or indirectly might offer protection against the onset of metabolic damage and promote healthy aging.

To this end, Howitz and colleagues performed an in vitro screen to identify small molecule activators of SIRT1 (Howitz et al., 2003). Resveratrol, a natural polyphenolic compound present in various dietary components such as mulberries, peanuts,

Table 1. Subjects' Baseline Characteristics

	Placebo	Resveratrol	P value
Age (years)	52.5 ± 2.1	52.5 ± 2.1	-
Body weight (kg)	100.1 ± 3.5	99.6 ± 3.7	0.50
BMI (kg/m ²)	31.59 ± 0.74	31.45 ± 0.82	0.48
Fat percentage (%)	26.44 ± 0.53	26.44 ± 0.53	-
VO _{2max} (ml.kg ⁻¹ .min ⁻¹)	24.96 ± 1.30	24.80 ± 1.00	0.83
Systolic blood pressure (mmHg)	131 ± 3.1	132 ± 3.0	0.22
Diastolic blood pressure (mmHg)	82 ± 2.5	83 ± 2.6	0.20
Glucose (mmol/l)	5.44 ± 0.10	5.44 ± 0.13	0.96
Insulin (mU/l)	16.37 ± 1.76	15.38 ± 2.05	0.67
Triglycerides (mmol/l)	1.86 ± 0.19	1.92 ± 0.21	0.80
Nonesterified fatty acids (μmol/l)	357 ± 69	320 ± 31	0.56

Subject characteristics at the start of the intervention (day 0). Values are given as means ± SEM (n = 11).

grapes, and red wine, was identified as the most potent activator of SIRT1 (Howitz et al., 2003). Recently, however, it was shown that resveratrol may not activate SIRT1 directly (Beher et al., 2009; Pacholec et al., 2010), but rather exerts its effects on SIRT1 through activation of AMPK (Baur et al., 2006; Cantó et al., 2009, 2010; Feige et al., 2008; Hawley et al., 2010; Um et al., 2010), although additional direct SIRT1 activation is not completely excluded (Dai et al., 2010). Regardless of the mode of activation, resveratrol treatment in mice fed a high-calorie diet consistently improved various health parameters, including glucose homeostasis, endurance, and survival (Baur et al., 2006; Lagouge et al., 2006; Pearson et al., 2008; Sun et al., 2007), and has therefore been suggested to act as a calorie restriction mimetic. However, so far no human studies have been reported that have systematically examined the metabolic effects of resveratrol in vivo.

Here, we gave obese but otherwise healthy subjects a dietary supplement containing 99% pure *trans*-resveratrol (resVida) over 30 days and examined whole-body energy expenditure, substrate utilization, ectopic lipid storage, mitochondrial function, and lipolysis in adipose tissue and skeletal muscle using a combination of in vivo and ex vivo measurements. Our data show that like calorie restriction, resveratrol supplementation lowers energy expenditure and improves metabolic profile as well as general health parameters.

RESULTS

Study Design and Plasma Biochemistry

Eleven obese but otherwise healthy male volunteers without a family history of diabetes or any other endocrine disorder participated in this study. Baseline characteristics of the subjects are included in Table 1. Subjects participated in two experimental trials: (1) a placebo and (2) a resveratrol (150 mg/day [99%] resVida) (provided by DSM Nutritional Products, Ltd.) condition in a randomized, double-blind, crossover design with a 4 week wash-out period. Subjects were instructed to take the first

Table 2. Plasma Biochemistry

	Placebo	Resveratrol	P value
Resveratrol (ng/ml)	Not detectable	182.59 ± 30.33	-
Dihydroresveratrol (ng/ml)	Not detectable	289.14 ± 93.57	-
Glucose (mmol/l)	5.28 ± 0.15	5.06 ± 0.13	0.05
Insulin (mU/l)	11.94 ± 1.11	10.31 ± 1.25	0.04
HOMA index	2.80 ± 0.20	2.43 ± 0.24	0.03
Triglycerides (mmol/l)	2.29 ± 0.23	2.16 ± 0.21	0.03
Nonesterified fatty acids (μmol/l)	572 ± 77	621 ± 38	0.59
Leptin (ng/ml)	14.28 ± 1.98	12.91 ± 1.84	0.04
Adiponectin (μg/ml)	6.47 ± 0.55	6.45 ± 0.56	0.95
CRP (ng/ml)	1.52 ± 0.35	1.33 ± 0.31	0.11
IL-1β (pg/ml)	1.33 ± 0.27	0.94 ± 0.15	0.20
IL-6 (pg/ml)	3.13 ± 0.67	2.42 ± 0.38	0.09
IL-8 (pg/ml)	4.94 ± 0.59	4.28 ± 0.25	0.19
TNF-α (pg/ml)	16.15 ± 2.27	15.14 ± 2.03	0.04
Leukocytes (10 ⁹ /l)	7.03 ± 0.44	6.48 ± 0.39	0.03
ALAT (U/l)	31.91 ± 2.21	28.09 ± 1.54	0.02

Plasma values after 30 days of resveratrol or placebo supplementation. Values are given as means ± SEM (n = 11). See also Table S1.

supplement on the day after the baseline measurements (day 1) and the last supplement in the evening on day 29.

To ensure that the subjects adhered to the study protocol and to confirm systemic conversion of resveratrol to dihydroresveratrol (DHR), total (sum of conjugated and unconjugated resveratrol) and free plasma levels of both compounds were analyzed each week during the 30 day period of resveratrol or placebo supplementation. Whereas no resveratrol or DHR could be detected in the placebo group, both compounds were present in plasma of resveratrol-supplemented subjects (Table 2, levels at day 30 are shown and are representative for the whole intervention period). Whereas measurement of plasma resveratrol demonstrated compliance to the study protocol and indicated that the compound was well absorbed, measurement of DHR confirmed that resveratrol was efficiently metabolized, especially as the plasma levels of DHR exceeded those of resveratrol after an overnight fast. No detectable levels of free resveratrol and free DHR were observed in the plasma in both the resveratrol and placebo periods, also confirming efficient metabolism. It is important to note that although the dosage of 150 mg of resveratrol per day is around 133- to 266-fold lower compared to the high doses of 200–400 mg/kg/day used to supplement mice (Baur et al., 2006; Lagouge et al., 2006), plasma resveratrol levels in our human intervention (231 ng/ml on average during the 30 days) were even higher than those obtained in mice (10–120 ng/ml) (Lagouge et al., 2006). These differences may be due to different metabolic rates of resveratrol between humans and mice and therefore suggest that resveratrol may exert its effects at different concentration ranges in different mammals.

To ensure that resveratrol supplementation did not cause adverse effects, we screened plasma and blood of the subjects for several general health parameters. Clinical chemistry,

Table 3. Clinical Improvement after Resveratrol

	Placebo	Resveratrol	P value
24 hr respiratory quotient	0.89 ± 0.007	0.91 ± 0.006	0.09
Respiratory quotient daytime	0.89 ± 0.004	0.91 ± 0.003	0.001
Respiratory quotient nighttime	0.87 ± 0.007	0.88 ± 0.009	0.18
24 hr energy expenditure (MJ/day)	11.86 ± 0.29	11.91 ± 0.29	0.64
Sleeping metabolic rate first night (MJ/day)	8.09 ± 0.24	7.75 ± 0.23	0.007
Sleeping metabolic rate second night (MJ/day)	8.06 ± 0.22	7.90 ± 0.18	0.06
Diet-induced thermogenesis (MJ/day)	1.02 ± 0.13	1.14 ± 0.17	0.33
Physical activity index	1.49 ± 0.02	1.50 ± 0.01	0.37
Systolic blood pressure (mmHg)	130.5 ± 2.7	124.7 ± 3.1	0.006
Diastolic blood pressure (mmHg)	81.6 ± 2.8	80.0 ± 2.9	0.18
Mean arterial pressure (mmHg)	97.9 ± 2.7	94.9 ± 2.9	0.02

Energy metabolism (n = 10), and blood pressure (n = 11) after 30 days of resveratrol or placebo supplementation. Values are given as means ± SEM. See also Table S2.

hematology, and coagulation analysis revealed no adverse effects after 30 days of resveratrol (see Table S1 available online). Plasma ALAT concentrations were significantly lower after resveratrol compared to placebo (Table 2). Also, leptin levels and leukocytes in the plasma were significantly lower in resveratrol-treated subjects (Table 2). In line with the reduced leukocyte count, resveratrol also lowered some markers of systemic inflammation, including IL-6 and TNF- α (Table 2). Electrocardiograms (ECGs) were inconspicuous and did not raise clinical concern in any subject. No clinical adverse events were reported during the resveratrol supplementation.

Next, we assessed whether resveratrol also exerted positive effects on plasma markers that predict the metabolic risk for development of diabetes and shorter life span. After 30 days of resveratrol, plasma glucose and insulin concentrations were lower compared to placebo (Table 2), resulting in a lower HOMA index, indicative of improved insulin sensitivity (Table 2). Plasma triglyceride concentrations were significantly lower after resveratrol compared to placebo. No differences were observed in plasma nonesterified fatty acids (NEFAs) (Table 2).

Clinical Improvement after Resveratrol Supplementation

As calorie restriction was described to associate with reduced absolute and body weight-adjusted 24 hr energy expenditure and sleeping energy expenditure (Heilbronn et al., 2006), we sought to investigate whether resveratrol treatment induced similar metabolic adaptations. Indeed, resveratrol supplementation for a period of 30 days had a profound effect on resting energy expenditure (Table 3). Subjects had a significantly lower sleeping metabolic rate (SMR) compared to placebo, even though 24 hr energy expenditure was similar between resveratrol and placebo (Table 3). Although calorie restriction causes meta-

bolic adaptations also partly through weight loss, we found no effect on body mass (99.9 ± 3.9 kg versus 99.6 ± 2.5 kg, in resveratrol versus placebo, $p = 0.43$). Respiratory quotient (RQ) values over 24 hr tended to be higher after resveratrol supplementation, which was largely accounted for by higher RQ values during the daytime (Table 3, the complete time course for the RQ and the energy expenditure over 24 hr is shown in Table S2). The higher RQ in the resveratrol group is especially apparent after periods of feeding and suggests improved metabolic flexibility, i.e., the ability to switch between energy substrates. No differences were observed in diet-induced thermogenesis or physical activity index (Table 3).

Next, we investigated whether resveratrol also exerted favorable effects on other general health parameters. As long-term calorie restriction in humans (Lefevre et al., 2009; Meyer et al., 2006) and resveratrol treatment in mice (Lagouge et al., 2006) was shown to ameliorate cardiac function, we examined whether resveratrol also exerts beneficial effects on blood pressure. Resveratrol significantly lowered systolic blood pressure by ~ 5 mmHg, while resveratrol had no effect on diastolic blood pressure (Table 3). Mean arterial pressure was significantly lower after resveratrol supplementation (Table 3).

Postprandial Substrate Utilization and Tissue Lipolysis

Mounting evidence implicates SIRT1 as a switch in substrate utilization, for instance from glucose to fatty acid oxidation under low-nutrient conditions (Cantó and Auwerx, 2009; Feige et al., 2008). Therefore, we next investigated whether resveratrol is able to increase fat oxidation in adipose tissue and skeletal muscle after a mixed meal by stimulating tissue lipolysis. The peak glucose and insulin responses after consuming a liquid test meal were reached after 30 min for placebo and after 60 min for resveratrol (Figures 1A and 1B). There was a tendency for NEFAs (area under the curve [AUC] 4–6 hr, $p = 0.13$) and free glycerol (AUC 4–6 hr, $p = 0.06$) to be lower in the late postprandial phase after resveratrol (Figures 1C and 1D). Resveratrol did not alter postprandial triglyceride and lactate responses (data not shown). Using the microdialysis technique, ethanol out/in ratios were determined to measure blood flow. At baseline, ethanol out/in ratios were not different after resveratrol supplementation compared to placebo, both in adipose tissue (0.81 ± 0.02 versus 0.81 ± 0.02 , respectively) and in skeletal muscle (0.46 ± 0.02 versus 0.49 ± 0.02 , respectively). Furthermore, resveratrol did not affect postprandial adipose tissue and skeletal muscle blood flow (data not shown). The interstitial glycerol concentration in adipose tissue was slightly lower in the resveratrol condition in the mid and late postprandial phases, although it did not reach statistical significance (AUC 2–4 hr, $p = 0.14$; AUC 4–6 hr, $p = 0.13$) (Figure 1E). There were no differences in interstitial glucose, pyruvate, and lactate responses in adipose tissue between placebo and resveratrol (data not shown). For skeletal muscle, there were no differences in interstitial glucose, pyruvate, lactate, and glycerol concentrations (glycerol data shown Figure 1F). Interestingly, energy expenditure in the postprandial period was significantly lower after resveratrol supplementation (AUC, $p = 0.02$) (Figure 1G). During the late postprandial phase (4–6 hr), RQ tended to be higher (AUC 4–6 hr, $p = 0.07$) (Figure 1H), and fat oxidation was decreased in the resveratrol condition (AUC 4–6 hr, $p = 0.007$) (Figure 1I).




Figure 1. Resveratrol Decreases Postprandial Energy Expenditure and Lowers Adipose Tissue Lipolysis

(A–I) Data are obtained on whole-body (A–D) by microdialysis (E and F) and indirect calorimetry (G–I). Plasma metabolites during the postprandial microdialysis test after 30 days of placebo or resveratrol supplementation are shown as follows: glucose response (A), insulin response (B), NEFA response (C), free glycerol response (D). Interstitial glycerol responses in adipose tissue (E) and skeletal muscle (F) during the postprandial microdialysis test are shown. Indirect calorimetry results during the postprandial microdialysis test are shown as follows: energy expenditure (G), respiratory quotient (H), fat oxidation (I). Values are given as means \pm SEM ($n = 10$).

Molecular Mechanism of Resveratrol Treatment

To clarify the mechanism of action of resveratrol, we performed microarray analysis on vastus lateralis muscle biopsies. We found 469 genes to be differentially expressed between placebo and resveratrol supplementation, 219 of which were increased and 250 decreased (Figure 2A). We performed gene set enrichment analysis (GSEA) to define the pathways that were affected by resveratrol and to compare the expression profile with previous studies in mouse (Lagouge et al., 2006). Several gene sets related to mitochondrial oxidative phosphorylation were up-regulated, whereas pathways linked to inflammation were down-regulated upon resveratrol supplementation (Table S3). Indeed, when analyzing expression of the individual genes in the oxidative phosphorylation-related gene sets, we observed a marked increase (Figure 2B, left panel), while for cytokine signaling, there was a clear decrease (Figure 2B, right panel). Importantly, these effects are highly similar to the effects observed in mice treated with resveratrol (Figure 2C), even though the effects in the latter are more pronounced, probably due to longer treatment time and their identical genetic and environmental background.

Since resveratrol was shown to activate AMPK, we measured levels of phosphorylated AMPK on the Thr172 residue of the α subunit—a marker for its activation. Indeed, increased AMPK phosphorylation was observed in muscle biopsies of the resveratrol-treated subjects (Figures 3A and S1A).

Mitochondrial Metabolism

Our microarray data clearly suggested strong involvement of mitochondrial function in the beneficial effects of resveratrol. We hence performed more detailed analyses of mitochondrial function. Mitochondrial DNA (mtDNA) copy number in the resveratrol condition was similar to the values obtained after placebo (994.8 ± 101.4 versus 1074.7 ± 109.9 AU in resveratrol versus placebo, $p = 0.20$). Also, neither the protein content of the individual structural components of the individual OXPHOS complexes nor the mean of all these complexes revealed differences in mitochondrial density in resveratrol compared to placebo supplementation (Figures 3B and S1B). On the other hand, protein content of the AMPK downstream effector SIRT1 (Cantó et al., 2009) as well as the mitochondrial master regulator




Figure 2. Resveratrol Increases Oxidative Phosphorylation Gene Expression in Man and Mice

(A) One-way hierarchical clustering of genes significantly changed in a microarray of muscle vastus lateralis of subjects receiving resveratrol (RSV) or placebo. In muscle, 469 genes were differentially expressed between placebo and RSV ($n = 10$, $p < 0.05$).

(B) Gene set enrichment analysis (GSEA) of muscle microarray revealed that gene sets related to mitochondrial oxidative phosphorylation were significantly increased (left panel) and cytokine signaling decreased (right panel) following resveratrol supplementation in humans.

(C) Previously published microarray data of mice treated with 400 mpkd RSV (Lagouge et al., 2006) were reanalyzed by GSEA, showing, like the human data, a marked enrichment of oxidative phosphorylation genes. See also Table S3.

PGC-1 α were significantly increased after 30 days of resveratrol (Figures 3C and S1C), as was citrate synthase activity (Figure 3D), a common marker for mitochondrial activity.

Mitochondrial function can also be assessed in vivo by measurement of phosphocreatine (PCr) recovery rate after exercise (Schrauwen-Hinderling et al., 2007). To this end, single leg extension exercise was performed for 5 min with a weight corresponding to 60% of maximal capacity, which was determined with an incremental maximal test on the same ergometer on a different day. Low- to medium-intensity exercise was chosen to prevent acidification of the muscle, which is known to affect PCr recovery. Spectra were acquired 2 min before exercise, during the 5 min of knee extension exercise, and during the subsequent 5 min of recovery (rest). As targeted, PCr levels decreased during the knee-extension exercise until a steady state was reached. However, mean PCr recovery half time (PCr- $t_{1/2}$) was unchanged by resveratrol compared to placebo (Figure 3E).

To functionally characterize mitochondrial oxidative phosphorylation in more detail, we measured mitochondrial respiration using different substrate combinations. State 2 respiration (i.e., respiration in the presence of exogenous substrates alone)

was not different between resveratrol versus placebo on any of the substrate combinations studied (data not shown). ADP-stimulated (state 3) respiration on a lipid substrate (malate + octanoyl-carnitine, MO) tended to be higher after resveratrol supplementation ($p = 0.075$, Figure 3F). State 3 respiration upon the complex I-linked substrates malate + glutamate (MG) was unaffected (Figure 3G). Respiration upon parallel electron input to both complex I and II was $\sim 10\%$ higher upon resveratrol. Thus, state 3 respiration upon malate + octanoyl-carnitine + glutamate (MOG) was significantly higher in subjects receiving resveratrol (Figure 3H). Similar differences were observed for state 3 respiration upon malate + octanoyl-carnitine + glutamate + succinate (MOGS) (Figure 3H), but not in the absence of octanoyl-carnitine (malate + glutamate + succinate, MGS) (Figure 3H). Maximal FCCP-induced uncoupled respiration, measured in the presence of octanoyl-carnitine, reflecting the maximal capacity of the electron transport chain, was also higher after 30 days of resveratrol (Figure 3I). State 4o respiration (reflecting mitochondrial proton leak) was similar between resveratrol and placebo condition (Figure 3J). Similar results were obtained if respiration rates were not corrected for mtDNA copy number.




Figure 3. Resveratrol Increases AMPK Activity, Mitochondrial Efficiency, and Respiration on Fatty Acid Substrates

(A) After 30 days of resveratrol or placebo, a muscle biopsy was obtained from the vastus lateralis muscle. Of total protein extracts from the vastus lateralis muscle, 50 μ g of protein was used to check the expression levels of several proteins by western blotting. Shown in (A) is the level of phosphorylation of residue Thr172 of the AMPK α subunit (top panel), indicative of AMPK activity, obtained by western blotting in a total of nine subjects per group (representative subset is shown). Total level of the AMPK α protein is shown in the bottom panel. The ratio of resveratrol to placebo is shown on the right of (A). Relative quantification of the ratio of pAMPK to AMPK is shown in Figure S1A.

(B) The protein content of the individual complexes of the electron transport chain is quantified by western blotting in vastus lateralis muscle of 11 subjects per group. An antibody cocktail that detects all five complexes is used, and the values are given as means \pm SEM for the individual complexes as well as for the average expression of all the complexes. A representative western blot is included in Figure S1B.

(C) SIRT1 and PGC-1 α protein levels in vastus lateralis muscle by western blotting ($n = 8$ for SIRT1 and $n = 11$ for PGC-1 α ; a representative subset is shown). The relative expression of both proteins is corrected for the loading control, tubulin for SIRT1 and actin for PGC-1 α . The ratio of resveratrol to placebo is shown on the right of (C). The relative quantification of the western blots is shown in Figure S1C.

(D) Citrate synthase activity was significantly increased in vastus lateralis muscle of resveratrol (RSV)-treated subjects ($n = 11$). Values are given as means \pm SEM, * $p < 0.05$.

(E) In vivo mitochondrial function expressed as PCr half-time ($n = 11$). Values are given as means \pm SEM.

(F–J) Evaluation of ex vivo mitochondrial function in vastus lateralis muscle: ADP-stimulated respiration (state 3) upon a lipid substrate (F); state 3 respiration fueled by complex I-linked substrates (G); state 3 respiration upon parallel electron input into complex I and II, * $p < 0.05$ (H); maximally uncoupled respiration upon FCCP, * $p < 0.05$ (I); mitochondrial respiration uncoupled from ATP synthesis (state 4o) (J). Values are given as means \pm SEM ($n = 10$). M, malate; O, octanoyl-carnitine; G, glutamate; S, succinate.

Lipid Accumulation in Liver and Skeletal Muscle

Since our data show that resveratrol clearly induced a shift in mitochondrial substrate selection, we tested whether this was also reflected in liver and skeletal muscle lipid accumulation. Intrahepatic lipid (IHL) content was lower after 30 days of resveratrol supplementation in comparison to placebo (Figure 4A). This was paralleled by lower plasma ALAT values, as mentioned before, both indicating improved liver function. The mean intramyocellular lipid (IMCL) area fraction was \sim 2-fold higher in the resveratrol group (Figure 4B). The increase in lipid accumulation was more pronounced in fibers identified as slow, oxidative (type 1) fibers than in type 2 muscle fibers (Figure 4B).

DISCUSSION

Resveratrol, which was discovered in a small-molecule screen as a potent SIRT1 activator (Howitz et al., 2003), has been extensively studied in animal and cellular studies with promising results (Baur et al., 2006; Lagouge et al., 2006). Here, we show

that resveratrol supplementation in humans exerted favorable metabolic adaptations that in many aspects mimic the effects of calorie restriction and/or endurance training (Civitarese et al., 2007; Heilbronn et al., 2006; Larson-Meyer et al., 2006, 2008; Lefevre et al., 2009). These metabolic adaptations include a reduction in SMR, blood pressure, and hepatic lipid content, an improvement in skeletal muscle intrinsic mitochondrial function and several plasma markers of general health, an increase in IMCL content, as well as an increase in skeletal muscle PGC-1 α protein content. These data extend findings, which so far have been observed only in cell and rodent models, to the human situation, showing that resveratrol has promising beneficial metabolic effects, and suggest that resveratrol has the potential to improve metabolic health in subjects at risk for developing the metabolic syndrome.

Resveratrol exerts significant effects on energy metabolism. SMR was significantly lower following 30 days of resveratrol supplementation, without changing 24 hr energy expenditure. It should be noted that SMR is the component of human energy




Figure 4. Resveratrol Decreases IHL Content but Increases Intramyocellular Lipid Content

(A) Ectopic lipid deposition after 30 days of placebo or resveratrol supplementation. Typical lipid regions of hepatic ^1H -MR spectra from a subject receiving placebo (left) and resveratrol (right) at 3T, scaled to the water resonance (reference), are shown in (A). The CH_2 peak is used for quantification; the area under the curve is proportional to the lipid content in the liver. Quantification revealed that IHL content was reduced by resveratrol ($n = 9$), $*p < 0.05$.

(B) Images of representative cross-section of the vastus lateralis muscle from a subject receiving placebo (top) and resveratrol (bottom). Sections are stained for intramyocellular lipids with oil red O staining (in red), muscle laminin (in blue), and type 1 muscle fibers (in green) (400 \times magnification). IMCL content significantly increased by resveratrol treatment in muscle fibers, which was mostly accounted for by an increased lipid storage in type 1 muscle fibers ($n = 10$), $*p < 0.05$. Values are given as means \pm SEM.

metabolism that is most sensitive to metabolic changes—as it is not affected by physical activity—and small differences in sleeping energy expenditure can be detected with high accuracy. In line with this, we observed that basal and postprandial energy expenditure was also lower after 30 days of resveratrol supplementation. The 2%–4% reduction in energy expenditure upon resveratrol treatment is consistent with the effects observed after calorie restriction (6% reduction) (Heilbronn et al., 2006; Martin et al., 2007).

It is important to note that basal and postprandial energy expenditure were reduced rather than increased by resveratrol in our human study, as was true for mice (Lagouge et al., 2006). Although our energy expenditure data are opposite to the effects seen in mice, a lowering of resting metabolic rate and SMR is likely a reflection of improved metabolic efficiency and completely in line with the endurance training or calorie restriction-like effects of resveratrol (Heilbronn et al., 2006; Martin et al., 2007). Although the dose used in our human study was \sim 200-fold lower than doses used in the mouse studies, we reached similar plasma resveratrol concentrations. We cannot exclude, however, that metabolism of resveratrol is different between mouse and man and, possibly more importantly, that timing of treatment (30 days in our study versus 4–6 months in mice [Baur et al., 2006; Lagouge et al., 2006]) significantly impacts physiological outcome.

Prolonged calorie restriction (during 6 months) has also been suggested to increase the expression of genes encoding proteins involved in mitochondrial biogenesis and function (Civitarese et al., 2007). Similarly, our microarray data indicate increased mitochondrial gene expression in muscle following resveratrol supplementation. In fact, we showed that this induction is likely to be mediated by AMPK—which is activated by resveratrol—and resulted in increased SIRT1 and PGC-1 α protein content, accompanied by increased citrate synthase activity, suggesting that mitochondrial activity was effectively improved.

Moreover, detailed mitochondrial characterization revealed that resveratrol had beneficial effects on mitochondrial respiration when octanoyl-carnitine was used as a substrate, but not when only glutamate was used. These data suggest that resveratrol specifically improves muscle fat oxidative mitochondrial capacity. Interestingly, we have recently found comparable effects in PGC-1 α -overexpressing mice, showing an improved intrinsic mitochondrial function (i.e., respiration per mitochondrion), but only when fatty acids are used as a substrate (Hoeks et al., 2011). The fact that mtDNA copy number, OXPHOS protein content, and PCr recovery were not changed in resveratrol-treated subjects suggests that 30 days resveratrol treatment mostly affects mitochondrial efficiency, not abundance. It is possible that more long-term treatment would cause these parameters to change as well.

Interestingly, IMCL content was markedly increased after 30 days of resveratrol supplementation. Together with the improvement in muscle fat oxidative capacity and the other beneficial metabolic adaptations like lowering of circulating triglyceride and glucose levels, the present data hint toward endurance training-like effects of resveratrol (Dubé et al., 2008; Meex et al., 2010). Consistent with data in rats, where resveratrol has been shown to reduce hepatic lipid synthesis (Ahn et al., 2008; Arichi et al., 1982), we observed reduced IHL content. Recent data suggest that endurance training is also able to lower IHL content (Kantartzis et al., 2009), as was calorie restriction, although this effect was mainly attributed to a reduction in body weight (Larson-Meyer et al., 2006; Lim et al., 2011). Taken together with the reduced plasma triglycerides and increased muscle fatty acid oxidation, we hypothesize that fat is liberated from peripheral depots to be metabolized by the muscle. Again, here our data suggest that resveratrol mimics the effect of calorie restriction and endurance training. Also, we have investigated postprandial metabolism, but found only a reduction in total energy expenditure that was reflected by a lower fat oxidation

during the late postprandial phase—a change that is reminiscent of the role of SIRT1 in regulating the efficient switch in energy substrate utilization (Cantó et al., 2009, 2010). Although postprandial lipolysis tended down, this does not refute our hypothesis of increased fat mobilization, but rather confirms the idea of improved metabolic flexibility.

A striking finding in our study was the resveratrol-induced reduction of systolic blood pressure by 5 mmHg. In rodents, resveratrol is also vasoactive and has been shown to cause vasodilatation and to improve aortic endothelial function in diabetic mice (Wang et al., 2011), to reduce heart rate (Lagouge et al., 2006), and even to lower blood pressure (Rivera et al., 2009). Also, in human obese subjects, endothelial function and cardiovascular health dose-dependently improved after 1 week of resveratrol supplementation (Wong et al., 2010). Similarly, healthy nonobese individuals also improved their cardiovascular risk after 6 months of calorie restriction, as evidenced by a reduction in blood pressure (Lefevre et al., 2009). Another indication that general health was improved upon resveratrol treatment was the decreased expression levels of genes of inflammatory pathways, as were plasma levels of several inflammatory markers and leukocyte numbers.

Our data also point toward favorable effects on glucose homeostasis after 30 days of resveratrol supplementation in obese subjects. Indeed, HOMA index was improved after resveratrol, suggesting favorable effects on insulin sensitivity. These beneficial effects of resveratrol on metabolism are in concordance with several findings of resveratrol supplementation in animals (Baur et al., 2006; Cantó et al., 2009; Lagouge et al., 2006; Pearson et al., 2008; Sun et al., 2007). Unfortunately, we could not determine if these effects resulted in improved whole-body insulin sensitivity.

In conclusion, we demonstrate beneficial effects of resveratrol supplementation for 30 days on the metabolic profile in healthy obese males, which seems to reflect effects observed during calorie restriction (Table S4). Although most of the effects that we observed were modest, they were very consistently pointing toward beneficial metabolic adaptations. Furthermore, there were no effects on safety parameters, and no adverse events were reported. Therefore, resVida was safe and well tolerated at the tested concentration. Future studies should investigate the long-term and dose-dependent metabolic effects of resveratrol supplementation in order to further establish whether resveratrol supplementation has the potential to overcome the metabolic aberrations that are associated with obesity in humans.

EXPERIMENTAL PROCEDURES

The study protocol was reviewed and approved by the Medical Ethical Committee of Maastricht University Medical Center (MUMC). All study participants gave written informed consent before initiation of the study.

Subject Characteristics

Eleven healthy, obese, male volunteers without family history of diabetes or any other endocrine disorder participated in this study (Table 1). None of the subjects was on medication or engaged in sports activities for more than 2 hr per week. Body composition was determined by a dual-energy X-ray absorptiometry scan (DEXA, Discovery A; Hologic, Bedford, MA), and maximal aerobic capacity was measured as described (Kuipers et al., 1985).

Clinical Study Design

Subjects participated in two experimental trials: a placebo and a resVida (150 mg/day *trans*-resveratrol [99.9%; provided by DSM Nutritional Products, Ltd.]) condition, in a randomized double-blind crossover design with a 4 week wash-out period. Subjects were instructed to take the first supplement on the day after baseline measurements (day 1) and the last supplement in the evening on day 29. The subjects were instructed to abstain from alcoholic beverages and foods containing substantial amounts of resveratrol (e.g., wine, red grapes, peanuts, and berries) and were advised not to take any other food supplements during the study period. Compliance with these instructions was confirmed by verbal declaration of the subjects. Subjects were advised to maintain their normal living, activity, and sleeping patterns during the intervention period. At the start (day 0) and end (day 30) of both intervention periods (resveratrol and placebo), blood samples were analyzed for general safety parameters including clinical chemistry, hematology, and coagulation values. A 12-lead ECG (Laméris, Veenendaal, The Netherlands) was performed at the beginning and end of both the resveratrol and placebo intervention. Each experimental trial lasted 4 weeks, during which the subjects came on a weekly basis (days 0, 7, 14, 21, and 30) to the university. The weekly checkup took place in the morning after an overnight fast and included a measurement of body mass and withdrawal of a small blood sample for the analysis of resveratrol (original and metabolites) to confirm compliance to the protocol. On day 28 in the evening, subjects came to the university for proton magnetic resonance spectroscopy (¹H-MRS) measurements of the liver to quantify IHL content, and postexercise PCr recovery rate was examined by ³¹P-MRS to estimate in vivo mitochondrial function (Schrauwen-Hinderling et al., 2007). To standardize food intake, subjects had lunch with the same food items in the two conditions and, after lunch, stayed fasted until the start of the measurement at 17 hr.

After the MRS measurements on day 28, subjects stayed in the respiration chamber during 36 hr to allow measurement of 24 hr substrate oxidation and energy expenditure (Schoffelen et al., 1997). Before their stay in the respiration chamber, a standardized evening meal was provided. In the respiration chamber, subjects were fed in energy balance (2332.5 kcal/day, 13.1 g of protein, 54.0 g of carbohydrate, 32.9 g of fat) and followed an activity protocol as described (Schrauwen et al., 1997). In the morning of day 30, after subjects left the respiration chamber, a muscle biopsy was taken to investigate ex vivo mitochondrial respiration, which was followed by the withdrawal of a fasting blood sample for the analysis of the effect of resveratrol on circulating substrates. Hereafter, adipose tissue and skeletal muscle lipolysis was examined by means of microdialysis.

Plasma Biochemistry

To check compliance, resveratrol metabolites were measured by mass spectrometry in plasma on days 0, 7, 14, 21, 29, and 30 as described in the Supplemental Experimental Procedures.

In the morning of day 30, after a standardized overnight fast for 12 hr and during the postprandial microdialysis test, blood samples were withdrawn for the determination of plasma metabolites according to standard procedures. Full experimental detail is described in the Supplemental Experimental Procedures.

Blood Pressure

On day 0 and day 30, blood pressure was measured after an overnight fast. By placing an automatic inflatable cuff (Omron Healthcare, Hamburg, Germany) on the nondominant arm in the resting condition, systolic and diastolic blood pressure was measured in triplicate. Mean systolic and diastolic blood pressure values were used to calculate the mean arterial pressure.

Lipid Accumulation in Liver

On day 28, before subjects underwent the respiration chamber measurement, ¹H-MRS was used to quantify IHL on a 3T whole-body scanner (Achieva, Philips Healthcare, Best, The Netherlands) using a five-element coil as described (Hamilton et al., 2011), but with a repetition time of 4000 ms, echo time of 37 ms, and number of averages of 64. To minimize motion artifacts, subjects were asked to breathe in the rhythm of the measurement and to be at end-expiration during acquisition of spectra. To determine the intensity of the lipid peak, the water signal was suppressed using frequency-selective prepulses.

The unsuppressed water resonance was used as internal reference (number of averages = 32), and spectra were fitted with AMARES (Vanhamme et al., 1997) in the jMURI software (Naressi et al., 2001). Values are given as T2-corrected ratios (according to Hamilton et al., 2011) of the CH₂ peak, relative to the unsuppressed water resonance (as percentage).

³¹P-MRS-Based Measurement of Mitochondrial Function

On day 28, ³¹P-MRS measurements were performed in vastus lateralis muscle on a 1.5T whole-body scanner (Intera, Philips Health Care, Best, The Netherlands) essentially according to an established methodology (Schrauwen-Hinderling et al., 2007).

Muscle Biopsy

On day 30, when subjects left the respiration chamber, a muscle biopsy was taken from the vastus lateralis muscle under local anesthesia (2% lidocaine), as previously described (Phielix et al., 2008). A portion of the muscle tissue was directly frozen in melting isopentane and stored at -80°C until assayed. Another portion (~30 mg) was immediately placed in ice-cold preservation medium for determination of ex vivo mitochondrial respiration (Phielix et al., 2008).

Molecular and Protein Expression

Mitochondrial DNA copy number, gene expression by microarray, and protein expression by western blot were performed according to standard procedures as described in the Supplemental Experimental Procedures.

High-Resolution Respirometry

Permeabilized muscle fibers were immediately prepared from the muscle tissue collected in the preservation medium, as described elsewhere (Boushel et al., 2007; Phielix et al., 2008). Subsequently, the permeabilized muscle fibers (~2.5 mg wet weight) were analyzed for mitochondrial function using an oxygraph (OROBOROS Instruments, Innsbruck, Austria) (Hoeks et al., 2010).

Intramycellar Lipids

Fresh cryosections (5 μm) were stained for IMCLs by oil red O staining combined with fibertyping and immunolabeling of the basal membrane marker laminin to allow quantification of IMCL, as described (Koopman et al., 2001).

Postprandial Substrate Utilization and Tissue Lipolysis

In ten subjects, the lipolytic effects of resveratrol in adipose tissue and skeletal muscle were successfully determined by microdialysis, essentially according to Goossens et al., 2004. A full description of the microdialysis method is provided in the Supplemental Information.

Statistical Analysis

Kolmogorov-Smirnov normality test was performed to evaluate normality distribution. Student's paired t test was used to compare placebo and resVida supplementation in normally distributed data; otherwise, Wilcoxon signed-rank test was used. For the microdialysis test day, postprandial AUC of plasma and interstitial metabolites and indirect calorimetry data were calculated using the trapezium rule. In addition to the total AUC (0–6 hr after meal ingestion), the early (0–2 hr), mid (2–4 hr), and late (4–6 hr) AUCs were also calculated to obtain more detailed information about the time course of postprandial responses. A p value <0.05 was considered statistically significant. Data are reported as mean ± SEM. Statistical analyses were performed using the statistical program SPSS 16.0 for Mac OS X.

ACCESSION NUMBERS

Raw microarray data sets have been submitted to NCBI Gene Expression Omnibus (GSE32357).

SUPPLEMENTAL INFORMATION

Supplemental Information includes one figure, four tables, Supplemental Experimental Procedures, and Supplemental References and can be found with this article online at doi:10.1016/j.cmet.2011.10.002.

ACKNOWLEDGMENTS

This study was funded by TI Food and Nutrition. A VICI grant (918.96.618) and a VENI grant (916.11.136) for innovative research from the Netherlands Organization for Scientific Research (NWO) supports the work of P.S. and V.S.-H., respectively. The work in the Auwerx laboratory is supported by the European Research Council (sirtuins; ERC-2008-AdG231-118), Swiss National Science Foundation, the Velux Foundation, and Ecole Polytechnique Fédérale. J.A. is the Nestle Chair in Energy Metabolism. R.H.H. is supported by a Rubicon fellowship of the Netherlands Organization for Scientific Research. I.K. is employed at DSM Nutritional Products Ltd., Kaiseraugst, Switzerland. The authors would like to thank DSM Nutritional Products Ltd. for providing us with the resVida and placebo capsules and for performing the resveratrol and DHR analysis. The authors thank Jos Stegen for his excellent technical assistance with the biochemical analysis and Mark Boekschoten from the Netherlands Nutrigenomics Centre for the microarray analysis.

Received: June 11, 2011

Revised: September 20, 2011

Accepted: October 11, 2011

Published online: November 1, 2011

REFERENCES

- Ahn, J., Cho, I., Kim, S., Kwon, D., and Ha, T. (2008). Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. *J. Hepatol.* 49, 1019–1028.
- Arichi, H., Kimura, Y., Okuda, H., Baba, K., Kozawa, M., and Arichi, S. (1982). Effects of stilbene components of the roots of *Polygonum cuspidatum* Sieb. et Zucc. on lipid metabolism. *Chem. Pharm. Bull. (Tokyo)* 30, 1766–1770.
- Barger, J.L., Walford, R.L., and Weindruch, R. (2003). The retardation of aging by caloric restriction: its significance in the transgenic era. *Exp. Gerontol.* 38, 1343–1351.
- Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 444, 337–342.
- Behr, D., Wu, J., Cumine, S., Kim, K.W., Lu, S.C., Atangan, L., and Wang, M. (2009). Resveratrol is not a direct activator of SIRT1 enzyme activity. *Chem. Biol. Drug Des.* 74, 619–624.
- Boushel, R., Gnaiger, E., Schjerling, P., Skovbro, M., Kraunsøe, R., and Dela, F. (2007). Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. *Diabetologia* 50, 790–796.
- Burnett, C., Valentini, S., Cabreiro, F., Goss, M., Somogyvári, M., Piper, M.D., Hodginott, M., Sutphin, G.L., Leko, V., McElwee, J.J., et al. (2011). Absence of effects of Sir2 overexpression on lifespan in *C. elegans* and *Drosophila*. *Nature* 477, 482–485.
- Cantó, C., and Auwerx, J. (2009). Caloric restriction, SIRT1 and longevity. *Trends Endocrinol. Metab.* 20, 325–331.
- Cantó, C., Gerhart-Hines, Z., Feige, J.N., Lagouge, M., Noriega, L., Milne, J.C., Elliott, P.J., Puigserver, P., and Auwerx, J. (2009). AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature* 458, 1056–1060.
- Cantó, C., Jiang, L.Q., Deshmukh, A.S., Matak, C., Coste, A., Lagouge, M., Zierath, J.R., and Auwerx, J. (2010). Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. *Cell Metab.* 11, 213–219.
- Civitaresse, A.E., Carling, S., Heilbronn, L.K., Hulver, M.H., Ukropcova, B., Deutsch, W.A., Smith, S.R., and Ravussin, E.; CALERIE Pennington Team. (2007). Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. *PLoS Med.* 4, e76.
- Crews, D.E. (2005). Artificial environments and an aging population: designing for age-related functional losses. *J. Physiol. Anthropol. Appl. Human Sci.* 24, 103–109.

- Dai, H., Kustigian, L., Carney, D., Case, A., Considine, T., Hubbard, B.P., Perni, R.B., Riera, T.V., Szczepankiewicz, B., Vlasuk, G.P., and Stein, R.L. (2010). SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. *J. Biol. Chem.* **285**, 32695–32703.
- Dubé, J.J., Amati, F., Stefanovic-Racic, M., Toledo, F.G., Sauers, S.E., and Goodpaster, B.H. (2008). Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited. *Am. J. Physiol. Endocrinol. Metab.* **294**, E882–E888.
- Feige, J.N., Lagouge, M., Canto, C., Strehle, A., Houten, S.M., Milne, J.C., Lambert, P.D., Matak, C., Elliott, P.J., and Auwerx, J. (2008). Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. *Cell Metab.* **8**, 347–358.
- Goodrick, C.L., Ingram, D.K., Reynolds, M.A., Freeman, J.R., and Cider, N. (1990). Effects of intermittent feeding upon body weight and lifespan in inbred mice: interaction of genotype and age. *Mech. Ageing Dev.* **55**, 69–87.
- Goossens, G.H., Blaak, E.E., Saris, W.H., and van Baak, M.A. (2004). Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. *J. Clin. Endocrinol. Metab.* **89**, 2690–2696.
- Hamilton, G., Yokoo, T., Bydder, M., Cruite, I., Schroeder, M.E., Sirlin, C.B., and Middleton, M.S. (2011). In vivo characterization of the liver fat ¹H MR spectrum. *NMR Biomed.* **24**, 784–790.
- Hawley, S.A., Ross, F.A., Chevzoff, C., Green, K.A., Evans, A., Fogarty, S., Towler, M.C., Brown, L.J., Ogunbayo, O.A., Evans, A.M., and Hardie, D.G. (2010). Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. *Cell Metab.* **11**, 554–565.
- Heilbronn, L.K., de Jonge, L., Frisard, M.I., DeLany, J.P., Larson-Meyer, D.E., Rood, J., Nguyen, T., Martin, C.K., Volaufova, J., Most, M.M., et al; Pennington CALERIE Team. (2006). Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. *JAMA* **295**, 1539–1548.
- Herranz, D., Muñoz-Martin, M., Cañamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., and Serrano, M. (2010). Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. *Nat Commun* **1**, 3.
- Hoeks, J., van Herpen, N.A., Mensink, M., Moonen-Kornips, E., van Beurden, D., Hesselink, M.K., and Schrauwen, P. (2010). Prolonged fasting identifies skeletal muscle mitochondrial dysfunction as consequence rather than cause of human insulin resistance. *Diabetes* **59**, 2117–2125.
- Hoeks, J., Arany, Z., Phielix, E., Moonen-Kornips, E., Hesselink, M.K., and Schrauwen, P. (2011). Enhanced lipid -but not carbohydrate- supported mitochondrial respiration in skeletal muscle of PGC-1 α overexpressing mice. *J. Cell Physiol.*, in press. Published online April 25, 2011. 10.1002/jcp.22812.
- Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., Zipkin, R.E., Chung, P., Kisilewski, A., Zhang, L.L., et al. (2003). Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* **425**, 191–196.
- Kantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., Königsrainer, A., Königsrainer, I., Kröber, S., Niess, A., et al. (2009). High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. *Gut* **58**, 1281–1288.
- Koopman, R., Schaart, G., and Hesselink, M.K. (2001). Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. *Histochem. Cell Biol.* **116**, 63–68.
- Kuipers, H., Verstappen, F.T., Keizer, H.A., Geurten, P., and van Kranenburg, G. (1985). Variability of aerobic performance in the laboratory and its physiologic correlates. *Int. J. Sports Med.* **6**, 197–201.
- Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 α . *Cell* **127**, 1109–1122.
- Larson-Meyer, D.E., Heilbronn, L.K., Redman, L.M., Newcomer, B.R., Frisard, M.I., Anton, S., Smith, S.R., Alfonso, A., and Ravussin, E. (2006). Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. *Diabetes Care* **29**, 1337–1344.
- Larson-Meyer, D.E., Newcomer, B.R., Heilbronn, L.K., Volaufova, J., Smith, S.R., Alfonso, A.J., Lefevre, M., Rood, J.C., Williamson, D.A., and Ravussin, E.; Pennington CALERIE Team. (2008). Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. *Obesity (Silver Spring)* **16**, 1355–1362.
- Lefevre, M., Redman, L.M., Heilbronn, L.K., Smith, J.V., Martin, C.K., Rood, J.C., Greenway, F.L., Williamson, D.A., Smith, S.R., and Ravussin, E.; Pennington CALERIE team. (2009). Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. *Atherosclerosis* **203**, 206–213.
- Lim, E.L., Hollingsworth, K.G., Aribisala, B.S., Chen, M.J., Mathers, J.C., and Taylor, R. (2011). Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* **54**, 2506–2514.
- Lin, S.J., Defossez, P.A., and Guarente, L. (2000). Requirement of NAD and SIR2 for life-span extension by calorie restriction in *Saccharomyces cerevisiae*. *Science* **289**, 2126–2128.
- Martin, C.K., Heilbronn, L.K., de Jonge, L., DeLany, J.P., Volaufova, J., Anton, S.D., Redman, L.M., Smith, S.R., and Ravussin, E. (2007). Effect of calorie restriction on resting metabolic rate and spontaneous physical activity. *Obesity (Silver Spring)* **15**, 2964–2973.
- McCay, C.M., Crowell, M.F., and Maynard, L.A. (1989). The effect of retarded growth upon the length of life span and upon the ultimate body size. *Nutrition* **5**, 155–171.
- Meex, R.C., Schrauwen-Hinderling, V.B., Moonen-Kornips, E., Schaart, G., Mensink, M., Phielix, E., van de Weijer, T., Sels, J.P., Schrauwen, P., and Hesselink, M.K. (2010). Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. *Diabetes* **59**, 572–579.
- Meyer, T.E., Kovács, S.J., Ehsani, A.A., Klein, S., Holloszy, J.O., and Fontana, L. (2006). Long-term caloric restriction ameliorates the decline in diastolic function in humans. *J. Am. Coll. Cardiol.* **47**, 398–402.
- Naressi, A., Couturier, C., Devos, J.M., Janssen, M., Mangeat, C., de Beer, R., and Graveron-Demilly, D. (2001). Java-based graphical user interface for the MRUI quantitation package. *MAGMA* **12**, 141–152.
- Pacholec, M., Bleasdale, J.E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R.S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., et al. (2010). SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. *J. Biol. Chem.* **285**, 8340–8351.
- Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N., Swindell, W.R., Kamara, D., Minor, R.K., Perez, E., et al. (2008). Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. *Cell Metab.* **8**, 157–168.
- Phielix, E., Schrauwen-Hinderling, V.B., Mensink, M., Lenaers, E., Meex, R., Hoeks, J., Kooi, M.E., Moonen-Kornips, E., Sels, J.P., Hesselink, M.K., and Schrauwen, P. (2008). Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients. *Diabetes* **57**, 2943–2949.
- Rivera, L., Morón, R., Zarzuelo, A., and Galisteo, M. (2009). Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. *Biochem. Pharmacol.* **77**, 1053–1063.
- Rogina, B., and Helfand, S.L. (2004). Sir2 mediates longevity in the fly through a pathway related to calorie restriction. *Proc. Natl. Acad. Sci. USA* **101**, 15998–16003.
- Rutanen, J., Yaluri, N., Modi, S., Pihlajamäki, J., Vääntinen, M., Itkonen, P., Kaululainen, S., Yamamoto, H., Lagouge, M., Sinclair, D.A., et al. (2010). SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. *Diabetes* **59**, 829–835.

- Schoffelen, P.F., Westerterp, K.R., Saris, W.H., and Ten Hoor, F. (1997). A dual-respiration chamber system with automated calibration. *J. Appl. Physiol.* *83*, 2064–2072.
- Schrauwen, P., van Marken Lichtenbelt, W.D., Saris, W.H., and Westerterp, K.R. (1997). Changes in fat oxidation in response to a high-fat diet. *Am. J. Clin. Nutr.* *66*, 276–282.
- Schrauwen-Hinderling, V.B., Kooi, M.E., Hesselink, M.K., Jeneson, J.A., Backes, W.H., van Echteld, C.J., van Engelshoven, J.M., Mensink, M., and Schrauwen, P. (2007). Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects. *Diabetologia* *50*, 113–120.
- Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., and Zhai, Q. (2007). SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. *Cell Metab.* *6*, 307–319.
- Tissenbaum, H.A., and Guarente, L. (2001). Increased dosage of a sir-2 gene extends lifespan in *Caenorhabditis elegans*. *Nature* *410*, 227–230.
- Um, J.H., Park, S.J., Kang, H., Yang, S., Foretz, M., McBurney, M.W., Kim, M.K., Violette, B., and Chung, J.H. (2010). AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. *Diabetes* *59*, 554–563.
- Vanhamme, L., van den Boogaart, A., and Van Huffel, S. (1997). Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. *J. Magn. Reson.* *129*, 35–43.
- Wang, N., Ko, S.H., Chai, W., Li, G., Barrett, E.J., Tao, L., Cao, W., and Liu, Z. (2011). Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNF α . *Am. J. Physiol. Endocrinol. Metab.* *300*, E195–E201.
- Wong, R.H., Howe, P.R., Buckley, J.D., Coates, A.M., Kunz, I., and Berry, N.M. (2010). Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. *Nutr. Metab. Cardiovasc. Dis.* *21*, 851–856. Published online July 29, 2010.